AC0682

N/A

Report date: 2022/08/26 14:15:15
NME

Base Information

Drug NameAC0682
Drug Alias NameAC682AC-682AC-0682
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEstrogen receptor alpha degraders
TargetsEstrogen receptor alpha
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAccutar Biotechnology Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAccutar Biological Science And Technology (Shanghai) Co Ltd
Inactive CompaniesAccutar Biotechnology Inc
Active IndicationsMetastatic breast cancer
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A